Recently, first data was published from an ongoing clinical trial (NCT01968109), in which anti-LAG-3 in combination with anti-PD-1 showed activity in melanoma patients who were relapsed or refractory to anti-PD-1/-PD-L1 therapy. Here, PDCD1 is linked to melanoma.